Russia's Nanolek commissions plant for production of nano-based drugs

12 January 2015

Nanolek, a joint venture between RusNano with Russian biotechnology company Epidbiomed and one of Russia’s largest drugmakers, which specializes in the production of drugs with nano-materials, has officially commissioned a new facility for the production of drugs for the treatment of cardiovascular, cancer and infectious diseases.

The new facility is expected to reach its design capacity by 2017. Total volume of investments in the project is 5 billion roubles ($120 million). The plant is located in the Orichevsky area of the Kirov region.

According to Denis Manturov, Russia’s Minister of Industry and Trade, the new plant will be fundamentally different to many Russian pharmaceutical producers and global drugmakers, operating their plants in Russia. This will be a full production cycle with the use of the own substances.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK